Pre-treatment or Post-treatment of Human Glioma Cells With BIX01294, the Inhibitor of Histone Methyltransferase G9a, Sensitizes Cells to Temozolomide

Glioblastoma (GBM) is a malignant, primary brain tumor, highly resistant to conventional therapies. Temozolomide (TMZ) is a first line therapeutic agent in GBM patients, however, survival of such patients is poor. High level of DNA repair protein, O(6)-methylguanine-DNA-methyltransferase (MGMT) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciechomska, Iwona Anna, Marciniak, Marta Patrycja, Jackl, Judyta, Kaminska, Bozena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224489/
https://www.ncbi.nlm.nih.gov/pubmed/30450051
http://dx.doi.org/10.3389/fphar.2018.01271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224489/
https://www.ncbi.nlm.nih.gov/pubmed/30450051
http://dx.doi.org/10.3389/fphar.2018.01271

Ejemplares similares